Mohammad Abu Zaid, MD
Hematology & Oncology · Kokomo, INNPI 1720392798
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,347 of the $2,033 with a category attached, or 66.2%. Janssen Research & Development, LLC accounts for 77.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $1,570 and has fallen 95.2% since, to $75 in 2025. That places this record below the midpoint for hematology & oncology clinicians in IN, where the typical reported total is $3,829.
Across 13 payments — averaging $156.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$2K
- Genentech, Inc.$150
- Incyte Corporation$122
- Iovance Biotherapeutics, Inc.$75
- Novartis$66
- Gilead$50
Across 217 payments — averaging $4537.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$520K
- Incyte Corporation$243K
- Pharmacyclics LLC, An Abbvie Company$221K
What the payments were for
- Travel & lodging$1,34766%
- Food & beverage$68634%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 7 | $1,570 |
| Genentech, Inc. | 1 | $150 |
| Incyte Corporation | 1 | $122 |
| Iovance Biotherapeutics, Inc. | 2 | $75 |
| Novartis | 1 | $66 |
| Gilead | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JAKAFI$122
How this compares
$2,033 in reported general payments places this provider in the 35th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluconazole | 18 | $814 |
| Acyclovir | 44 | $628 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $130 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Kokomo
- John SalterKokomo$19K
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Chandler ParkCorydon$661K
- Neel ShahDyer$464K
- Ahad SadiqFort Wayne$430K
- Ajay KandraMadison$408K
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.